These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12939386)

  • 21. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications.
    Briet M; Burns KD
    Clin Sci (Lond); 2012 Oct; 123(7):399-416. PubMed ID: 22671427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial calcification: cardiovascular function and clinical outcome.
    London GM
    Nefrologia; 2011; 31(6):644-7. PubMed ID: 22130278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular calcifications in uremia: old concepts and new insights.
    Derici U; El Nahas AM
    Semin Dial; 2006; 19(1):60-8. PubMed ID: 16423183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of uremia in apolipoprotein E-deficient mice.
    Bro S
    Dan Med Bull; 2009 Nov; 56(4):177-92. PubMed ID: 19939336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large artery structure and function in hypertension and end-stage renal disease.
    London GM; Guerin AP; Pannier B; Marchais SJ; Safar ME
    J Hypertens; 1998 Dec; 16(12 Pt 2):1931-8. PubMed ID: 9886879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of cardiovascular calcification in uremia.
    Mazzaferro S; Pasquali M; Cozzolino M
    Curr Vasc Pharmacol; 2011 Nov; 9(6):741-9. PubMed ID: 21824104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.
    Toussaint ND; Kerr PG
    Nephrology (Carlton); 2007 Oct; 12(5):500-9. PubMed ID: 17803475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants].
    Lajemi M; Gautier S; Benetos A
    Pathol Biol (Paris); 1999 Jun; 47(6):614-22. PubMed ID: 10472072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench.
    El-Abbadi M; Giachelli CM
    Curr Opin Nephrol Hypertens; 2005 Nov; 14(6):519-24. PubMed ID: 16205469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathophysiology of anaemia: focus on the heart and blood vessels.
    Metivier F; Marchais SJ; Guerin AP; Pannier B; London GM
    Nephrol Dial Transplant; 2000; 15 Suppl 3():14-8. PubMed ID: 11032352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Structural changes and vascular calcifications in uremia].
    Caramelo C; Goicoechea M; Albalate M; Nieto L; Melero R; Berlanga JR; López MD; González Pacheco F; Marrón B; Alvarez Arroyo MV; Castilla MA; Yagüe S; Deudero JJ; Ortiz A
    Nefrologia; 2001; 21(6):538-47. PubMed ID: 11881423
    [No Abstract]   [Full Text] [Related]  

  • 35. Pathophysiological mechanisms and consequences of cardiovascular calcifications: role of uremic toxicity.
    Chillon JM; Mozar A; Six I; Maizel J; Bugnicourt JM; Kamel S; Slama M; Brazier M; Massy ZA
    Ann Pharm Fr; 2009 Jul; 67(4):234-40. PubMed ID: 19596096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of atherosclerotic inflammation and calcification in subjects with end stage renal disease (ESRD) on hemodialysis to normal controls utilizing
    Bural GG; Torigian DA; Sözmen M; Houseni M; Alavi A
    Hell J Nucl Med; 2018; 21(3):169-174. PubMed ID: 30411726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders.
    Guérin AP; Pannier B; Marchais SJ; London GM
    Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):105-10. PubMed ID: 16481874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Can cardiovascular calcifications be prevented in chronic kidney disease?].
    Coen G; Manni M; Mantella D; Splendiani G
    G Ital Nefrol; 2006; 23 Suppl 34():S21-5. PubMed ID: 16633990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of calcification in blood and urine.
    Schlieper G; Westenfeld R; Brandenburg V; Ketteler M
    Semin Dial; 2007; 20(2):113-21. PubMed ID: 17374084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.